Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...

Prostate cancer incidence is increasing, especially in advanced stages, reversing previous declines and slowing mortality rate improvements. Racial disparities persist, with Black and Native American ...

Prostate cancer remains a critical health issue for men across the U.S., particularly among Black men. The issue will be ...